Clinical studies have shown that GLP-1 improves endothelial function in patients with type 2 diabetes (13), and transient GLP-1 administration is able to improve cardiovascular outcomes in patients with myocardial infarction (MI) (14) or congestive heart failure (CHF) (15,16). The gene discussed is GLP1R; the disease is myocardial infarction.